NCT07347808CompletedPhase 1
A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients
A Phase 1, Single-Dose, Open-Label, Parallel-Group Pharmacokinetic Study of VCT220 in Subjects With Moderate Renal Impairment and Matched Subjects With Normal Renal Function
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of VCT220 (other name: CX11) in subjects with moderate renal impairment compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations of VCT220 in subjects with renal impairment.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 22 Dec 2025
- Start date
- 25 Dec 2025
- Primary completion date
- 18 Jan 2026
- Lead sponsor
- Vincentage Pharma Co., Ltd
- Diseases
- Obesity
- NCT number
- NCT07347808
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 16
- From 25 Dec 2025 to the primary completion date, 18 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of prohibited medications affecting drug metabolism prior to dosing
Other illness
- History of hypersensitivity to GLP-1 receptor agonists or study drug components
- History of hypoglycemia
- History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- History of pancreatitis
- Clinically significant cardiovascular, hepatic, gastrointestinal, neurological, hematologic, endocrine, or psychiatric disease
- Positive tests for hepatitis B, hepatitis C, HIV, or syphilis
Other
- Pregnant or breastfeeding women
Who the study is looking for
- Male or female subjects aged 18 to 75 years
- Body mass index (BMI) between 18.5 and 32.0 kg/m²
- Able and willing to provide written informed consent
- Willing to comply with contraception requirements
- Moderate renal impairment group
- Absolute eGFR ≥30 and \<60 mL/min
- Diagnosis of chronic kidney disease for ≥3 months with stable renal function
- Normal renal function group:
- Absolute eGFR ≥90 and \<130 mL/min Matched to moderate renal impairment subjects by sex, age (±10 years), and BMI (±10%)
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Anhui Medical University Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.